Among clinically symptomatic Indigenous individuals, anti-HSV-1 IgM was detected in 17.1%, 21.2%, 12.5%, and 22% of those exhibiting urinary problems, genital wounds, genital warts, and urethral discharge, respectively (Table 3; Fig. 3). This evidence concerns the gene CD40LG and anogenital human papillomavirus infection.